Targeting SIRT1 - A multitasker

Drugs of the Future

Volumn 31, Issue 5, 2006, Pages 461-465

  Davies, Shelley L ^a   Bozzo, Jordi ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 (CYCLOPENTYLCARBOXAMIDO) 6 METHYL 4,5,6,7 TETRAHYDRO 1 BENZOTHIOPHENE 3 CARBOXAMIDE; 2 93 CYCLOHEXYL 4 OXO 4,5,6,7 TETRAHYDRO 3H CYCLOPENTAL[4.5]THIENOL[2.3 D]PYRIMIDIN 2 YLSULFANYL)ACETIC ACID; 2 [4 BENZYL 5 (1H INDOL 3 YLMETHYL) 4H 1,2,4 TRIAZOL 3 YLSULFANYL]ACETAMIDE; 4 OXOPENTANOIC ACID 3 ACETOXY 5 [2[E] (3 ACETOXYPHENYL)VINYL]PHENYL ESTER; 6 METHYL 2 PROPIONAMIDO 4,5,6,7 TETRAHYDRO 1 BENZOTHIOPHENE 3 CARBOXAMIDE; ACETIC ACID 4 [2[E] (3,5 BIS(METHOXYMETHOXY)PHENYL)VINYL]PHENYL ESTER; BUTEIN; ENZYME INHIBITOR; EX 527; FISETIN; HISTONE DEACETYLASE 3; HR 73; ISOLIQUIRITIGENIN; NICOTINAMIDE; PICEATANNOL; POLYPHENOL DERIVATIVE; PROTEIN; PROTEIN SIRT1; QUERCETIN; RESVERATROL; SIRT1 INHIBITOR; SIRTINOL; SIRTUIN; SMALL INTERFERING RNA; SPLITOMICIN; TRANS 3,4' DIACETOXY 5 (4 OXOPENTANOYLOXY)STILBENE; TRANS 4' ACETOXY 3,5 BIS(METHOXYMETHOXY)STILBENE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; WO 2005069998; WO 2005072412;

ALZHEIMER DISEASE; BLADDER CANCER; CANCER THERAPY; CLINICAL TRIAL; DIABETES MELLITUS; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LARYNX CANCER; OBESITY; REVIEW; STROKE; TRANSCRIPTION REGULATION;

EID: 33746338896     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2006.031.05.982834     Document Type: Review

References (25)

1. Picard, F., Kurtev, M., Chung, N. et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-γ. Nature 2004, 429(6993): 771-6.
2. Lin, J., Handschin, C., Spiegelman, B.M. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 2005, 1(6): 361-70.
3. Bordone, L., Motta, M.C., Picard, F. et al. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic β cells. PLoS Biol 2006, 4(2): e31.
4. Araki, T., Sasaki, Y., Milbrandt, J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 2004, 305(5686): 1010-3.
5. Raval, A.P., Dave, K.R., Perez-Pinzon, M.A. Resveratrol mimics ischemic preconditioning in the brain. J Cereb Blood Flow Metab 2005, Advanced online publication, December 14.
6. Chen, J., Zhou, Y., Mueller-Steiner, S., Chen, L.F., Kwon, H., Yi, S., Mucke, L., Gan, L. SIRT1 protects against microglia-dependent amyloid-β toxicity through inhibiting NF-κB signaling. J Biol Chem 2005, 280(48): 40364-74.
7. Geesaman, B.J., Brass, L. (Elixir Pharmaceuticals, Inc.). SIRT1 and genetic disorders. WO 2005004814.
8. Howitz, K.T., Bitterman, K.J., Cohen, H.Y. et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425(6954): 191-6.
9. Sinclair, D.A., Alexander-Bridges, M. (Harvard College; General Hospital Corp.). Compositions for treating or preventing obesity and insulin resistance disorders. WO 2005065667.
10. Andrus, M.B., Liu, J. (Brigham Young University). Novel sirtuin activating compounds and methods for making the same. WO 2005069998.
11. Garcia-Manero, G., Issa, J.P. Histone deacetylase inhibitors: A review of their clinical status as antineoplastic agents. Cancer Invest 2005, 23(7): 635-42.
12. Liu, T., Kuljaca, S., Tee, A., Marshall, G.M. Histone deacetylase inhibitors: Multifunctional anticancer agents. Cancer Treat Rev 2006, In press.
13. Alcendor, R.R., Kirshenbaum, L.A., Imai, S., Vatner, S.F., Sadoshima, J. Silent information regulator 2α, a longevity factor and class III histone deacetylase, is an essential endogenous apoptosis inhibitor in cardiac myocytes. Circ Res 2004, 95(10): 971-80.
14. Ota, H., Tokunaga, E., Chang, K. et al. Sirt1 inhibitor, sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 2006, 25(2): 176-85.
15. Ford, J., Jiang, M., Milner, J. Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res 2005, 65(22): 10457-63.
16. Milner, A.J. (University of York). Induction of apoptosis by inhibition of sirtuin SIRT1 expression. WO 2005078091.
17. Banham, A., Pulford, K., Liggins, A., Guinn, B. (Isis Innovation, Ltd.). Tumor associated antigens. WO 2003082916.
18. Pagans, S., Pedal, A., North, B.J. et al. SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol 2005, 3(2): e41.
19. Ott, M., Verdin, E.M., Jung, M. (University of California, Oakland). Compositions and methods for modulating sirtuin activity. WO 2005062952.
20. Distefano, P., Watson, A.D., Cannon, E.L., Navia, M.A., Curtis, R., Geesaman, B.J. (Elixir Pharmaceuticals, Inc.). Antiviral therapeutics. WO 2005072412.
21. Chong, Z.Z., Lin, S.H., Li, F., Maiese, K. The sirtuin inhibitor nicotinamide enhances neuronal cell survival during acute anoxic injury through AKT, BAD, PARP, and mitochondrial associated "anti-apoptotic" pathways. Curr Neurovasc Res 2005, 2(4): 271-85.
22. Sauve, A.A., Schramm, V.L. Sir2 regulation by nicotinamide results from switching between base exchange and deacetylation chemistry. Biochemistry 2003, 42(31): 9249-56.
23. Randomized trial of ARCON in larynx cancer (NCT00147732). ClinicalTrials.gov Web Site 2005, December 8.
24. Radiation therapy with or without carbogen and niacin in treating patients with bladder cancer (NCT00033436). ClinicalTrials.gov Web Site 2006, February 23.
25. Solomon, J.M., Pasupuleti, R., Xu, L., McDonagh, T., Curtis, R., DiStefano, P. S., Huber, L.J. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol 2006, 26(1): 28-38.